Evidence map›Paper›PMID 39473213›Full record

ReviewCurrent cancer drug targets2025

A Potential Role for Oridonin in Cancer Control: Mechanisms of Autophagy and Apoptosis.

Reza Arefnezhad, Sina Rahimi-Shatranlo, Bahman Rabiei, Hooman Zarei, Ahmad Nazari, Pouya Goleij, Fatemeh Mahmoudpour, Neshat Khalafi, Mohadeseh Hajighasemi, Tahereh Farkhondeh and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Reza ArefnezhadCoenzyme R Research Institute, Tehran, Iran.
Sina Rahimi-ShatranloYoung Researchers and Elite Club, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Bahman RabieiFaculty of Pharmacy, Shahid Beheshti University, Tehran, Iran.
Hooman ZareiDepartment of Anatomical Sciences, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ahmad NazariSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Pouya GoleijDepartment of Genetics, Sana Institute of Higher Education, Sari, Iran.
Fatemeh MahmoudpourStudent Research Committee, Department of Medical Laboratory Science, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Neshat KhalafiCoenzyme R Research Institute, Tehran, Iran.
Mohadeseh HajighasemiDepartment of Basic Medicine Sciences, Faculty of Biotechnology, Amol University of Special Modern Technologies, Amol, Iran.
Tahereh FarkhondehSchool of Pharmacy, Department of Basic, Birjand University of Medical Sciences, Birjand, Iran.
Mohamad SaminiDepartment of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeed SamarghandianDepartment of Physiology, Faculty of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the leading causes of mortality and morbidity worldwide. It is characterized by unmanaged cell proliferation and growth, leading to tumour formation with the potential to metastasize to various organs of the human body. Currently, several common therapeutic approaches exist to treat malignancies, including chemotherapy, surgery, and radiotherapy, which can be used to prevent the progression of malignancies. However, these therapeutic approaches often face challenges due to their cytotoxic impacts and various side effects. Ergo is currently researching a new treatment that effectively reduces cancer progression with minimal side effects. Emerging evidence suggests that harnessing herbal sources, which are both accessible and safe, can be useful in improving various disorders, including cancer. Oridonin, a diterpenoid isolated from the traditional Chinese medicinal herb Rabdosia rubescens, has shown significant potential in cancer therapy. Moreover, numerous pharmacological and biological capacities have been attributed to this naturally active compound, such as anti-oxidative, anti-inflammatory, anti-bacterial, and anti-viral influences. This review summarizes the current knowledge on oridonin's mechanisms of action, particularly its effects on autophagy and apoptosis. While apoptosis is a well-established pathway for eliminating cancer cells through DNA fragmentation, autophagy plays a complex role, acting as both a cytoprotective and cell death mechanism depending on the context. We provide a comprehensive evaluation of the relevant studies, highlighting oridonin's potential in cancer control and identifying areas for further research.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisAutophagyDiterpenes, KauraneNeoplasmsAnimalsHumansAntineoplastic Agents, PhytogenicDiterpenes, KauraneoridoninapoptosisAutophagycancercancer therapy.cytotoxicoridonin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.